Vamikibart clinical trials
Also written RO7200220.
How each study uses vamikibart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2019 | 1 |
| 2021 | 2 |
| 2023 | 2 |
Who runs them
Industry 6 · Other 0
Hoffmann-La Roche (5) · Eleven Biotherapeutics (1)
Studies
Open first, then newest update. How each study uses vamikibart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular EdemaCompletedPhase 2Hoffmann-La RocheNCT05151731Written as Vamikibart
- Vamikibart in Participants With Uveitic Macular EdemaCompletedPhase 3Hoffmann-La RocheNCT05642325Written as Vamikibart
- A Study to Investigate Vamikibart in Participants With Uveitic Macular EdemaCompletedPhase 3Hoffmann-La RocheNCT05642312Written as Vamikibart
- A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular EdemaCompletedPhase 2Hoffmann-La RocheNCT05151744Written as Vamikibart
- A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular EdemaCompletedPhase 1Hoffmann-La RocheNCT06771271Written as RO7200220
- Safety Study of Intravitreal EBI-031 Given as a Single or Repeat Injection to Subjects With Diabetic Macular EdemaWithdrawnPhase 1Eleven BiotherapeuticsNCT02842541Written as EBI-031
Codes
What other systems call vamikibart · ClinicalTrials.gg INT017084
- UNII (FDA) KP04MH1JTTVAMIKIBARTOne source FDA
- NCI Thesaurus C199126VamikibartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | KP04MH1JTT | VAMIKIBART | One source FDA |
| NCI Thesaurus | C199126 | Vamikibart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.